Category: 3. Business

  • Only one analyst has a sell rating on Nvidia – and he says ‘it feels fantastic’

    Only one analyst has a sell rating on Nvidia – and he says ‘it feels fantastic’

    By Brett Arends

    Lone Nvidia bear Jay Goldberg shares why he’s still not a buyer of the AI superstock

    Nvidia founder and CEO Jensen Huang, the man of the moment.

    How does it feel to be the only analyst on Wall Street who is bearish about AI superstock Nvidia Corp. (NVDA)?

    “It feels fantastic,” Jay Goldberg tells me with a laugh. “Everybody asks me this question.”

    Goldberg, a research analyst at Seaport Research Partners, is the only analyst with a “sell” or “underperform” recommendation on Nvidia’s stock. Of the other 65 (yes, really), 60 give stock a “buy” or “outperform” rating and five give it a neutral “hold,” according to FactSet.

    “I have never told my clients to ‘short’ Nvidia,” he adds, referring to the technique for trying to make money if a stock falls. “But I’ve always positioned my thesis as, ‘Nvidia is going to underperform the sector.’ And that has actually played out. If you look at the AI sector, Nvidia has underperformed since April 1 when I launched coverage.”

    Goldberg is a former research analyst at Deutsche Bank. He also worked in the tech sector. He spent a decade in China and remains in touch with former colleagues there, while staying on top of developments. One of the (many) reasons he’s skeptical about Nvidia’s stock at current levels is that Taiwan Semiconductor, the company that actually produces the physical chips, is already running at full capacity. “They’re sold out,” he says. “And once they’ve sold out, where does the upside come from?”

    But Goldberg’s analysis isn’t just about Nvidia stock. His thesis is important for everyone who invests in the stock market, even if they just have their 401(k) invested in broad-based index funds that track the S&P 500 SPX. When the last two bubbles burst, in 2000 and 2008, it wasn’t just the investments at the center of the mania – technology stocks and housing, respectively – that tanked. The entire market went down about 50%.

    A market is supposed to match buyers and sellers. If you run out of sellers, that’s when you get in trouble. One of the oldest saws on the street of shame is that a bubble doesn’t peak “until the last bear turns bullish.” (Based on the events of 1999-2000 and 2006-07, it’s probably more accurate to say it doesn’t peak until the last bear capitulates or gets fired.)

    Goldberg is standing his ground.

    “It’s complicated,” he says.” I’m getting increasingly bearish about the AI cycle, the AI bubble. I fully subscribe to this as a bubble. Semiconductors are cyclical. Eventually, gravity will reassert itself. This could end in six weeks. It could end in three years.”

    We’re already at the stage where big companies, particularly Nvidia, ChatGPT-owner OpenAI and others, are providing the capital to their own customers. This so-called “vendor financing” was a notorious feature of the dot-com and tech bubble of the late 1990s, and dragged everything down when the bubble burst.

    Goldberg says things could get “even crazier” as companies issue massive amounts of debt to fuel their expansion. And that is starting to happen.

    Meanwhile, the investment euphoria for the emerging technology of artificial intelligence has outstripped the proven demand from end customers.

    “I’m especially nervous about the demand side of the AI trade,” he says. “I don’t think we fully understand the use case of AI. Enterprise adoption is tepid,” referring to usage by businesses.

    A recent study by MIT found that 95% of the companies that have invested in AI have so far earned “zero return.” Meanwhile, up the road from MIT at Harvard Business School, the latest business review asks – with a straight face – “AI Companies Don’t Have a Profitable Business Model. Does That Matter?”

    As MarketWatch has recently written, hedge-fund manager Harris “Kuppy” Kupperman, among others, has already run a slide rule over the math of the AI mania and found it comes up short.

    Goldberg argues that many investors underestimate how expensive it is to run AI cloud-computing server farms, which need an enormous amount of electricity. He also says AI chips will be rendered obsolete far quicker than many in the industry say.

    “The more important question is not the physical life of the server, it’s the economic life of the server,” Goldberg says. “In 2022, if you had a GPU, you could pay for it in six months. Now the payback is still somewhere between 11/2 and two years.” That’s “still pretty good,” he says. But the direction is down. “What matters is the obsolescence factor.”

    This is an argument already made by Michael Burry, the hedge-fund manager made famous by Michael Lewis’s “The Big Short,” which successfully predicted the global financial crisis in 2008. Burry recently started betting against AI superstocks such as Nvidia. “He’s onto something,” Goldberg says.

    In a surprising and mysterious development, Burry just deregistered his hedge fund, Scion Asset Management, from the Securities and Exchange Commission. “On to much better things Nov. 25th,” he wrote. It’s not clear yet what Burry means. But if he’s a bear who’s capitulating, that’s another ominous sign.

    -Brett Arends

    This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

    (END) Dow Jones Newswires

    11-15-25 1238ET

    Copyright (c) 2025 Dow Jones & Company, Inc.

    Continue Reading

  • UN forum launches first “total balance sheet” transition guide for insurers at COP30 – United Nations Environment – Finance Initiative

    UN forum launches first “total balance sheet” transition guide for insurers at COP30 – United Nations Environment – Finance Initiative

    Belém, Brazil, November 2025 The United Nations-convened Forum for Insurance Transition (FIT) today unveiled a landmark global guide that links underwriting and investment portfolios of insurance and reinsurance companies through a pioneering set of “Total Balance Sheet Principles” for transition planning.

    A Total Balance Sheet Transition: A holistic transition plan guide linking the underwriting and investment portfolios of insurers and reinsurers” provides insurers, reinsurers and brokers with a practical, principles-based framework to develop and disclose credible, enterprise-wide transition plans. The guide defines the essential components of a total balance sheet approach—grounded in cognitive consonance—and sets out clear criteria, principles and practical examples that help insurers better identify and manage risks, opportunities and impacts, , strengthen financial resilience, and support real-economy transition outcomes.

    The new guide is the third deliverable of the FIT Transition Plan Project:

    • The first deliverable of the FIT Transition Plan Project, Closing the Gap (November 2024), introduced the foundations of transition planning for the insurance industry and mapped national policy and regulatory frameworks relevant to transition plans, climate and sustainability risk management, and disclosure across developed and developing countries.
    • The second deliverable, Underwriting the Transition (July 2025), provided deep-dive transition plan guidance tailored to insurance and reinsurance underwriting portfolios, outlining the respective roles of insurers, reinsurers and brokers.
    • This third deliverable—developed in two phases—operationalizes the convergence of underwriting and investment transition plans, ensuring that earlier FIT guidance can be implemented as part of one coherent Total Balance Sheet framework.

    Together, these deliverables form the most comprehensive, insurance-specific transition plan guidance available to date.

    Continue Reading

  • Cisco (CSCO) “Doesn’t Blow People Off,” Says Jim Cramer

    Cisco (CSCO) “Doesn’t Blow People Off,” Says Jim Cramer

    We recently published 11 Stocks Jim Cramer Talked About. Cisco Systems Inc. (NASDAQ:CSCO) is one of the stocks Jim Cramer recently discussed.

    Networking hardware equipment manufacturer Cisco Systems Inc. (NASDAQ:CSCO) reported its fiscal first-quarter earnings report on Wednesday. The results saw the firm report $14.88 billion in revenue and $1 in EPS which beat analyst estimates of $14.77 billion and $0.98. Citing orders from hyperscalers, Cisco Systems Inc. (NASDAQ:CSCO) outlined that its networking business saw revenue grow by 15% to $7.77 billion during the quarter. After yesterday’s close and the latest earnings, Cisco Systems Inc. (NASDAQ:CSCO)’s current forward P/E ratio sits at 19, according to Yahoo Finance. Cramer discussed the firm ahead of the earnings report and assured viewers that the Cisco Systems Inc. (NASDAQ:CSCO) of 2025 wasn’t equivalent to the one in 1999:

    Cisco (CSCO) “Doesn’t Blow People Off,” Says Jim Cramer

    “[On upcoming earnings] Yeah and we own it for the charitable trust. It’s not expensive by the way. Now the last time it was at these levels, it was very expensive. Now you’re talking about 1999, but that’s a company that sells at 16 times earnings. It’s not the one that’s historically blowing up to anybody. Doesn’t blow people off.

    While we acknowledge the potential of CSCO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

    READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

    Disclosure: None. This article is originally published at Insider Monkey.

    Continue Reading

  • Despite AI bubble fears, Warren Buffett’s Berkshire Hathaway buys shares of hyperscaler Alphabet

    Despite AI bubble fears, Warren Buffett’s Berkshire Hathaway buys shares of hyperscaler Alphabet

    Wall Street has been consumed for months with fears that the artificial intelligence boom is actually a bubble about to pop, but that didn’t stop Berkshire Hathaway from buying shares of a top AI hyperscaler.

    Warren Buffett’s conglomerate revealed in a regulatory filing late Friday that it purchased 17.8 million shares of Google parent Alphabet during the third quarter. The stock jumped 4% in after-hours trading yesterday.

    It was the biggest stock addition last quarter and was worth about $4.3 billion at the end of September. Berkshire also bought shares of Chubb, Domino’s Pizza, Sirius XM and Lennar.

    Meanwhile, Berkshire maintained its position in Amazon, another AI hyperscaler, in the third quarter.

    The addition of Alphabet comes amid a massive rally. Even after the most recent AI-fueled stock market selloff, Alphabet shares are still up 46% this year.

    To be sure, Alphabet has been on Berkshire’s radar in the past. In 2019, Buffett’s right-hand man at the time, the late Charlie Munger, admitted that he felt “like a horse’s ass for not identifying Google better. I think Warren feels the same way.”

    Back then, Google’s dominance in search piqued Berkshire’s interest. But today, the company is among the tech giants leading the charge into AI.

    Alphabet, Amazon, Meta Platforms and Microsoft alone are spending hundreds of billions of dollars a year with no signs of a slowdown.

    Morgan Stanley has estimated AI hyperscalers plan to spend about $3 trillion on data centers and other infrastructure through 2028.

    The relentless capital expenditures, much of which is coming via debt, have made Wall Street nervous about whether AI companies will be able to translate all those outlays into sustainable revenue and profits.

    With Buffett due to step down as Berkshire’s CEO by year’s end, it’s not immediately clear whether he, successor Greg Abel, or another top executive made the call to buy Alphabet stock.

    And investors may not hear directly from the “Oracle of Omaha” on the matter. In a letter published Monday, Buffett said he’ll be “going quiet,” and will no longer write Berkshire’s annual report, nor talk “endlessly” at the annual meeting.

    Leading up to Buffett’s departure, Berkshire has been taking a cautious stance on the stock market as well as company acquisitions, sending its cash pile to record highs.

    Buffett’s closely followed stock portfolio continued to shrink overall, as last quarter marked three straight years of net selling. The most recent round of selling included more shares of Apple, which Berkshire has been steadily offloading for more than a year.

    Continue Reading

  • JBS Venture Agrees to Buy Hickman’s in Push for US Egg Market – Bloomberg.com

    1. JBS Venture Agrees to Buy Hickman’s in Push for US Egg Market  Bloomberg.com
    2. Mantiqueira USA Announces Acquisition of Hickman’s Egg Ranch, Marking U.S. Expansion  GlobeNewswire
    3. Hickman’s Family Farm set to be purchased by Brazilian company  12News
    4. Hickman’s Egg Ranch sold to global egg producer, ending Arizona ownership  azcentral.com and The Arizona Republic
    5. Hickman’s Family Farm to be acquired by Brazilian company, food organization in joint venture  KTAR News 92.3 FM

    Continue Reading

  • Review Highlights IGHV Testing Complexities in CLL

    Review Highlights IGHV Testing Complexities in CLL

    Immunoglobulin heavy chain variable (IGHV) testing has become an important prognostic and therapeutic factor in chronic lymphocytic leukemia (CLL), but advances in technologies such as next-generation sequencing (NGS) have amplified both the importance and the complexity of IGHV analysis, according to a new review.

    In the review, which was published in the International Journal of Laboratory Hematology, corresponding author Tanya L. Gillan, PhD, of Canada’s Dalhousie University, and colleagues outlined how the latest technological and methodological advances have shaped emerging strategies in diagnosing and treating CLL.1

    The authors noted that IGHV status has long been linked with patient outcomes. Patients with mutated IGHV have repeatedly been found to have substantially longer overall survival (OS) than those with unmutated IGHV, they explained. Furthermore, IGHV status has been shown to have the second-greatest impact on 5-year survival of any biomarker, second only to TP53 abnormalities.2

    Patients are considered to have unmutated IGHV if they have at least 98% homology to the germline sequence. Cases with homology below 98% or which are borderline are generally deemed to be mutated, and those patients have a more favorable prognosis, Gillan and colleagues said. They said that IGHV mutational status does not evolve over time, so it only requires testing at diagnosis or before initiating treatment.

    IGHV status has also been linked with time to treatment and treatment response. One study found patients with unmutated IGHV had a median progression-free survival (PFS) of 14.6 years after 19 years of follow-up, compared to 4.2 years among patients with unmutated IGHV.3

    Gillan and colleagues next discussed the guidelines published by the European Research Initiative on CLL (ERIC) and the ways they have evolved over time to answer newly emerging questions.1 First published in 2007, the most recent updates of the guidelines were published in 2022 and 2024. One focus on the 2022 update, they said, is the impact of IGHV mutation status and B-cell receptor immunoglobulin stereotypy on treatment response, the authors said. Another point of emphasis is the growing potential of NGS in immunogenetic analysis.

    Gillan and colleagues said Sanger sequencing had long been considered the “gold standard” for IGHV testing, but they said its adoption was limited by its labor intensiveness, technical complexity, limited scalability, and lack of insight into subclonal architecture and intraclonal diversity. More recently, NGS has been found to match the performance of Sanger sequencing, the authors said, without the same drawbacks. Yet, they said current amplicon-based methods of NGS are limited by amplification bias. They said targeted capture NGS can avoid such biases. The investigators discussed the state of the art of IGHV analysis at length, adding that NGS analysis has opened up new insights and new opportunities to refine prognostication.

    Gillan and colleagues said one benefit of NGS is that it allows for the combination of multiple assays in a single run, allowing for assessment of multiple clinically relevant mutations—not just IGHV mutations—at once. However, they said the technical advancements will also further the need for additional standardization.

    Moving forward, they said a number of issues need to be resolved, including the limited concordance between NGS and flow cytometry methodologies for detecting subclonal B-cell populations. They said the clinical significance of IGHV clonotypes remains unclear. Other questions remain unanswered as well, they said.

    The authors said NGS testing has allowed for new insights into the biology of IGHV and how to interpret IGHV mutations.

    “The clinical significance of the various IGHV scenarios—including multiple clones, unproductive or absent clones, stereotyped subsets, subclones, and major or minor stereotyped subsets—as well as the impact of novel therapies on IGHV [somatic hypermutation], which may mitigate the poor prognosis associated with certain IGHV clones, will continue to evolve as research in this field progresses,” they concluded.

    References

    1. Wood RK, Elsharawi I, Goudie M, Bruyère H, Rahmani M, Gillan TL. The ABCs of IGHV testing in chronic lymphocytic leukaemia: current recommendations, ongoing challenges, and future directions. Int J Lab Hematol. Published online October 28, 2025. doi:10.1111/ijlh.70010
    2. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760. doi:10.1182/blood-2017-09-806398
    3. Thompson PA, Bazinet A, Wierda WG, et al. Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up. Blood. 2023;142(21):1784-1788. doi:10.1182/blood.2023020158

    Continue Reading

  • A Fresh Look at Intuit (INTU) Valuation After New AI Launches and Cherry Bekaert Partnership

    A Fresh Look at Intuit (INTU) Valuation After New AI Launches and Cherry Bekaert Partnership

    Intuit (INTU) is in the spotlight following a series of announcements on new AI capabilities across its core products. Expanded automation and intelligent insights now power QuickBooks, TurboTax, and Credit Karma.

    See our latest analysis for Intuit.

    Intuit’s flurry of AI-powered releases and a headline partnership with Cherry Bekaert have certainly kept the spotlight on its growth story. Even so, the share price hasn’t quite followed suit lately, with momentum cooling after early-year gains. Intuit’s 1-year total shareholder return sits at -3.1%, despite a strong 3-year figure of nearly 78%.

    If you’re keen to spot emerging opportunities beyond just major headlines, this is a great moment to broaden your perspective with fast growing stocks with high insider ownership

    With Intuit’s steady stream of innovation and analyst optimism, the key question emerges: does the current share price reflect all this future growth, or could investors be looking at a compelling entry point?

    Intuit’s last close comes in well below the most widely followed narrative’s fair value, hinting at unpriced growth that could surprise the market. Let’s look at the most important driver powering this perspective.

    The accelerating adoption of Intuit’s AI-driven all-in-one platform, including virtual teams of AI agents and human experts, positions the company to consolidate customers’ tech stacks, drive automation of workflows, and unlock substantial ROI for customers. This supports higher average revenue per customer (ARPC) and net margin expansion over time.

    Read the complete narrative.

    What’s behind this bullish outlook? Only the full narrative reveals the mix of game-changing digital adoption, margin leaps, and bold revenue bets that back up today’s optimistic price target. Don’t miss the details—the real drivers could shift the market’s view.

    Result: Fair Value of $807.12 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, ongoing challenges in Mailchimp recovery and softer international growth could quickly change the outlook if improvements stall or if markets weaken further.

    Find out about the key risks to this Intuit narrative.

    Switching gears, some investors look at the price-to-earnings ratio for signals. At 47.7x, Intuit’s valuation stands well above both the industry average (32.7x) and its own fair ratio of 43.2x. This gap suggests limited margin of safety, which could signal extra risk or justify the price if growth materializes.

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:INTU PE Ratio as at Nov 2025

    If you see things differently or want a clearer view, dig into the numbers yourself and shape your own perspective in just a few minutes, then Do it your way

    A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Intuit.

    Take your investing to the next level by leveraging expert-curated stock ideas. Uncover your next big winner today before the market catches on and leaves you behind.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include INTU.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • The AI bubble may be showing up in an unexpected place: the shady forecasts of future electricity demand—and skyrocketing bills

    The AI bubble may be showing up in an unexpected place: the shady forecasts of future electricity demand—and skyrocketing bills

    The forecasts are eye-popping: utilities saying they’ll need two or three times more electricity within a few years to power massive new data centers that are feeding a fast-growing AI economy.

    But the challenges — some say the impossibility — of building new power plants to meet that demand so quickly has set off alarm bells for lawmakers, policymakers and regulators who wonder if those utility forecasts can be trusted.

    One burning question is whether the forecasts are based on data center projects that may never get built — eliciting concern that regular ratepayers could be stuck with the bill to build unnecessary power plants and grid infrastructure at a cost of billions of dollars.

    The scrutiny comes as analysts warn of the risk of an artificial intelligence investment bubble that’s ballooned tech stock prices and could burst.

    Meanwhile, consumer advocates are finding that ratepayers in some areas — such as the mid-Atlantic electricity grid, which encompasses all or parts of 13 states stretching from New Jersey to Illinois, as well as Washington, D.C. — are already underwriting the cost to supply power to data centers, some of them built, some not.

    “There’s speculation in there,” said Joe Bowring, who heads Monitoring Analytics, the independent market watchdog in the mid-Atlantic grid territory. “Nobody really knows. Nobody has been looking carefully enough at the forecast to know what’s speculative, what’s double-counting, what’s real, what’s not.”

    Suspicions about skyrocketing demand

    There is no standard practice across grids or for utilities to vet such massive projects, and figuring out a solution has become a hot topic, utilities and grid operators say.

    Uncertainty around forecasts is typically traced to a couple of things.

    One concerns developers seeking a grid connection, but whose plans aren’t set in stone or lack the heft — clients, financing or otherwise — to bring the project to completion, industry and regulatory officials say.

    Another is data center developers submitting grid connection requests in various separate utility territories, PJM Interconnection, which operates the mid-Atlantic grid, and Texas lawmakers have found.

    Often, developers, for competitive reasons, won’t tell utilities if or where they’ve submitted other requests for electricity, PJM said. That means a single project could inflate the energy forecasts of multiple utilities.

    The effort to improve forecasts got a high-profile boost in September, when a Federal Energy Regulatory Commission member asked the nation’s grid operators for information on how they determine that a project is not only viable, but will use the electricity it says it needs.

    “Better data, better decision-making, better and faster decisions mean we can get all these projects, all this infrastructure built,” the commissioner, David Rosner, said in an interview.

    The Edison Electric Institute, a trade association of for-profit electric utilities, said it welcomed efforts to improve demand forecasting.

    Real, speculative, or ‘somewhere in between’

    The Data Center Coalition, which represents tech giants like Google and Meta and data center developers, has urged regulators to request more information from utilities on their forecasts and to develop a set of best practices to determine the commercial viability of a data center project.

    The coalition’s vice president of energy, Aaron Tinjum, said improving the accuracy and transparency of forecasts is a “fundamental first step of really meeting this moment” of energy growth.

    “Wherever we go, the question is, ‘Is the (energy) growth real? How can we be so sure?’” Tinjum said. “And we really view commercial readiness verification as one of those important kind of low-hanging opportunities for us to be adopting at this moment.”

    Igal Feibush, the CEO of Pennsylvania Data Center Partners, a data center developer, said utilities are in a “fire drill” as they try to vet a deluge of data center projects all seeking electricity.

    The vast majority, he said, will fall off because many project backers are new to the concept and don’t know what it takes to get a data center built.

    States also are trying to do more to find out what’s in utility forecasts and weed out speculative or duplicative projects.

    In Texas, which is attracting large data center projects, lawmakers still haunted by a blackout during a deadly 2021 winter storm were shocked when told in 2024 by the grid operator, the Electric Reliability Council of Texas, that its peak demand could nearly double by 2030.

    They found that state utility regulators lacked the tools to determine whether that was realistic.

    Texas state Sen. Phil King told a hearing earlier this year that the grid operator, utility regulators and utilities weren’t sure if the power requests “are real or just speculative or somewhere in between.”

    Lawmakers passed legislation sponsored by King, now law, that requires data center developers to disclose whether they have requests for electricity elsewhere in Texas and to set standards for developers to show that they have a substantial financial commitment to a site.

    Electricity bills are rising, too

    PPL Electric Utilities, which delivers power to 1.5 million customers across central and eastern Pennsylvania, projects that data centers will more than triple its peak electricity demand by 2030.

    Vincent Sorgi, president and CEO of PPL Corp., told analysts on an earnings call this month that the data center projects “are real, they are coming fast and furious” and that the “near-term risk of overbuilding generation simply does not exist.”

    The data center projects counted in the forecast are backed by contracts with financial commitments often reaching tens of millions of dollars, PPL said.

    Still, PPL’s projections helped spur a state lawmaker, Rep. Danilo Burgos, to introduce a bill to bolster the authority of state utility regulators to inspect how utilities assemble their energy demand forecasts.

    Ratepayers in Burgos’ Philadelphia district just absorbed an increase in their electricity bills — attributed by the utility, PECO, to the rising cost of wholesale electricity in the mid-Atlantic grid driven primarily by data center demand.

    That’s why ratepayers need more protection to ensure they are benefiting from the higher cost, Burgos said.

    “Once they make their buck, whatever company,” Burgos said, “you don’t see no empathy towards the ratepayers.”

    Continue Reading

  • $9B Mobilized to Regenerate Agrifood Landscapes and Support 12M Farmers Worldwide

    $9B Mobilized to Regenerate Agrifood Landscapes and Support 12M Farmers Worldwide

    Belém, Brazil, November 15, 2025 – The COP Action Agenda on Regenerative Landscapes (AARL) today announced a surge in investments to advance production, conservation, and restoration, advancing integrated solutions to deliver resilient agrifood systems. More than 40 organizations reported $9B+ in committed investment, covering more than 210 million hectares of land, reaching 12 million farmers across 90+ commodities and 110+ countries by 2030, highlighting significant progress since the initiative was launched at COP28.

    AARL – launched by the COP28 Presidency, the World Business Council for Sustainable Development (WBCSD), and Boston Consulting Group (BCG), with support from the UN Climate Change High-Level Champions – brings together farmers, agribusinesses, financiers, and leading non-state actors to aggregate, accelerate, and amplify collective action and investments to overcome barriers to scaling regenerative landscape approaches.

    Driving Scale and Impact

    Since the initiative’s launch at COP28, participation has significantly grown, expanding from 25 to 40+ organizations, including commodity traders, consumer goods companies, retailers, agtech providers, financial institutions, and other non-state actor partners.

    While the total land under regenerative transition reflects a stricter definition and revised expectations (resulting in a decrease since 2024), the maturity and quality of programs have advanced. The share of initiatives at-scale (10,000 hectares) has grown from 38% to 52%, and the proportion of programs with three or more partners has expanded from 16% to 40%. Investment has accelerated far beyond land growth, increasing more than fourfold from $2.2B in 2023 to $9B in 2025. Drawing from the AARL data, the Guidebook for Landscape Investments collates 12 case studies showcasing replicable success factors for landscape regeneration, highlighting the impact that agrifood companies can achieve when working collaboratively, putting in place holistic financial and technical support mechanisms for producers.

    However, data collection and reporting remain areas for improvement. Currently, 67% of responding participants are measuring carbon impacts in at least some programs, but only 38% are reporting on carbon outcomes. Reporting on soil health, biodiversity, water, and farmer livelihoods lags further behind, underscoring the challenges in identifying robust yet cost-effective monitoring, reporting and verification systems and the need for greater transparency.

    We see firsthand how business leadership, when coupled with inclusive multi-stakeholder collaboration, is indispensable to unlocking the full potential of regenerative landscapes.

    – Dan Ioschpe – Climate High-Level Champion – COP30, Brazil

    This work shows show how businesses can (and must) work shoulder-to-shoulder with local partners, governments, investors, and farmers to create regenerative landscapes that deliver measurable climate, nature, and social benefits. This is not a solo journey; it is collective action in its fullest sense.

    – Nigar Arpadarai – Climate High-Level Champion – COP29, Azerbaijan

    The 9B+ dollars committed to regenerating agri-food landscapes by businesses in the AARL demonstrate the scale of the transition underway in agriculture. The next phase of this initiative will showcase the results these $9B+ can deliver on the ground, and how this investment can de-risk the transition for farmers.

    – Diane Holdorf, Executive Vice President, World Business Council for Sustainable Development (WBCSD)

    The power of AARL is not only in the $9B its members are committing to regenerative landscapes, but also its unique model of place-based collaboration that can deliver impact at scale. We’re seeing evidence of this in the Landscape Accelerator Brazil.

    – Shalini Unnikrishnan, Managing Director & Senior Partner, Boston Consulting Group (BCG)

    Place-Based Acceleration in Brazil

    At COP29, AARL marked a pivotal step in moving from ambition to action with the launch of its first landscape accelerator: the Landscape Accelerator Brazil (LAB).

    Launched in partnership with Brazil’s Ministry of Agriculture, the LAB focuses on the Cerrado biome and Pará state (Amazon). Research from the LAB shows that restoring pastures and advancing regenerative practices across 50M+ hectares represents a $93B investment opportunity, with an average 19% internal rate of return for 610,000 farmers. This commercially bankable opportunity requires de-risking through blended finance approaches.

    A year in, the LAB has made significant progress to unleash this opportunity:

    • Blended finance: Quantifying the business case and financing stack needed to scale regenerative landscapes in Brazil
    • Harmonized measurement, reporting, and verification (MRV): Developing context-specific and streamlined metrics and MRV implementation guidance
    • Aligned policy: Identifying four key policy priorities to unlock private sector investment

    In 2026, the LAB aims to evolve into a co-investment platform focused on specific landscapes, with the ambition of mobilizing $5 billion by 2030 – as outlined in its Action Plan.

    Looking Ahead

    In 2024, AARL was identified as a mechanism supporting the delivery of the UNCCD COP16 Riyadh Action Agenda. Additionally, AARL will partner with the Resilient Agriculture Investment for net-Zero land degradation (RAIZ) accelerator, which the COP30 Presidency will announce on 19th November.

    Going forward, the AARL will replicate the accelerator blueprint in new geographies – starting with India in 2026. AARLwelcomes collaborators across agricultural landscapes in this global effort, including governments, businesses, financiers, producers, civil society, research organizations and other non-state actors.

    Continue Reading

  • Non-Invasive Tests Show Promise for Tracking Treatment Response in Semaglutide MASH Trial

    Non-Invasive Tests Show Promise for Tracking Treatment Response in Semaglutide MASH Trial

    Blood-based biomarkers and imaging measures may eventually serve as practical tools for monitoring disease activity in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to a new analysis.1

    The retrospective phase 2b study, which explored the use of various non-invasive tests (NITs) to assess response to semaglutide, adds to growing evidence that the drug not only improves metabolic parameters but may also produce early and measurable liver benefits detectable through blood-based and imaging biomarkers.

    If these NITs prove useful in further research, write the researchers, they could reduce reliance on repeated liver biopsies, which remain the current standard despite their limitations.

    Although biopsy-confirmed histology is required for clinical trials, repeated biopsies are burdensome for patients and challenging for trial execution. As drug development accelerates, there is increasing pressure to validate NITs, such as liver stiffness measurement, fibrosis scores, or circulating biomarkers, as surrogate indicators of treatment response.

    This new study, published in Alimentary Pharmacology & Therapeutics, assessed 268 patients with biopsy-confirmed MASH and fibrosis stages F1–F3 who completed 72 weeks of treatment and had both baseline and end-of-treatment biopsy and NIT measurements. Patients had been randomized to receive one of 3 semaglutide doses or a placebo. For this exploratory analysis, all semaglutide doses were pooled to increase statistical power.

    The investigators examined 17 unique NITs, including liver enzymes (ALT, AST), CK18 fragments, FibroScan-based metrics (controlled attenuation parameter and liver stiffness measure [LSM]), composite fibrosis scores (FIB-4, ELF, ADAPT), and proprietary biomarker panels such as NIS-4, MASEF, and several SomaSignal tests.

    Across the pooled semaglutide group, nearly all NITs showed meaningful reductions from baseline to week 72, with improvements emerging as early as week 28. Measures tied to inflammation, steatosis, or fibrosis demonstrated consistent downward trends. In contrast, the placebo group showed little change, reinforcing that the improvements were treatment related. These findings aligned with biopsy-based assessments from the original study, which showed higher rates of MASH improvement and lower rates of fibrosis progression among semaglutide recipients.

    To quantify whether NITs could serve as treatment-response markers, investigators defined “responders” as those achieving a ≥20% improvement in a given NIT (or ≥0.5-unit reduction for ELF based on prior clinical significance criteria). By this definition, semaglutide recipients had significantly more responders across nearly all NITs compared with placebo. For example, large proportions of semaglutide-treated patients demonstrated improved liver stiffness, fibrosis scores, steatosis markers, and inflammatory signatures. These NIT improvements frequently corresponded with histological improvement, supporting their potential utility as surrogate end points.

    The study also explored whether baseline NIT levels predicted spontaneous fibrosis improvement or progression in placebo recipients. In this prognostic assessment, lower baseline fibrosis-related NIT scores, such as FIB-4, ELF, PRO-C3, and the SomaSignal fibrosis score, were associated with greater likelihood of improvement. Conversely, higher baseline FIB-4 values were linked to fibrosis progression. These findings suggest that some NITs may capture disease trajectory independent of treatment, though larger validation studies are needed.

    Another evaluation focused on whether patients moved across clinically meaningful risk categories after treatment. In subgroups with elevated baseline risk, such as those with liver stiffness ≥8 kPa or ELF ≥9.8, a substantially higher proportion of semaglutide-treated individuals shifted into lower-risk categories compared with placebo. More than half of patients receiving semaglutide with elevated liver stiffness dropped below the 8-kPa threshold by week 72, compared with only 21% of placebo recipients. Similar patterns were observed for higher thresholds (12 kPa) and for ELF-based risk assessments.

    “LSM is of considerable interest given that it is already in use clinically to detect fibrosis in hepatic disease as part of risk stratification,” explained the researchers. Moreover, LSM is recommended in MASLD guidelines because of its convenience and low cost.”

    Collectively, these results support the concept that NITs may serve as meaningful indicators of treatment response and fibrosis improvement in MASH. However, the authors caution that this analysis was exploratory and not powered for regulatory validation. With no correction for multiple comparisons and the absence of long-term clinical outcomes, additional research, including the ongoing ESSENCE phase 3 trial of semaglutide treatment in patients with MASH,2 is needed before NITs can be adopted as formal surrogate end points.

    References

    1. Nitze LM, Ratziu V, Sanyal AJ, et al. Exploration of multiple non-invasive tests for assessing response to treatment in a semaglutide phase 2b trial in patients with MASH. Aliment Pharmacol Ther. Published online September 23, 2025. doi:10.1111/apt.70376

    2. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258

    Continue Reading